Erythropoietin as candidate for supportive treatment of severe COVID-19

Erythropoietin as candidate for supportive treatment of severe COVID-19

Abstract In light of the present therapeutic situation in COVID-19, any measure to improve course and outcome of seriously affected individuals is of utmost importance. We recap here evidence that supports the use of human recombinant erythropoietin (EPO) for ameliorating course and outcome of serio...

Full description

Bibliographic Details
Main Authors: Hannelore Ehrenreich, Karin Weissenborn, Martin Begemann, Markus Busch, Eduard Vieta, Kamilla W. Miskowiak
Format: Article
Language:English
Published: BMC 2020-06-01
Series:Molecular Medicine
Subjects:
SARS-CoV-2; recombinant human erythropoietin
EPO
respiratory function
inflammation
cytokine storm
neuroprotection
Online Access:http://link.springer.com/article/10.1186/s10020-020-00186-y

Internet

http://link.springer.com/article/10.1186/s10020-020-00186-y

Similar Items